Type of study in modified release formu­lation EMEA [Regulatives / Guidelines]

posted by fno Homepage – Belgium, 2014-03-13 12:16 (4482 d 17:05 ago) – Posting: # 12615
Views: 17,581

❝ "A multiple dose study is needed unless a single dose study has been performed with the highest strength which has demonstrated that the mean AUC(0-τ) after the first dose covers more than 90% of mean AUC(0-∞) for both test and reference, and consequently a low extent of accumulation is expected".


This does not seem so cryptic anyway...

Let's assume a once daily dosing is the standard regimen for the originator (reference) product.
You have to perform a BE single dose study with both test and reference formulations at the highest registered strength and compute AUC0-24h and AUC0-inf. If this study demonstrate that AUC0-24h > 0.9 × AUC0-inf for both test and reference, it is not necessary to perform a MD BE study.

Hope this helps.
—
Kind regards,
Fabrice

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
124 visitors (0 registered, 124 guests [including 17 identified bots]).
Forum time: 06:22 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5